title: [Advances of DNA damage repair and Cisplatin resistance mechanisms in lung cancer].
abstract: Lung cancer is the most common cause of death from cancer worldwide per year. Platinum-based combination chemotherapy is a main treatment of lung cancer. Cisplatin is adopted widely and used effectively in the first-line chemotherapy. Unfortunately, development of cisplatin resistance is a major obstacle to the success of lung caner. Cisplatin is a cell-cycle-non-specific cytotoxic drugs and its main target is DNA. Thus, defective DNA damage repair is one of the main mechanisms of cisplatin resistance. In this review, we will focus on the defective DNA damage repair in cisplatin resistance of lung cancer including nucleotide excision repair, DNA mismatch repair, DNA double-strand break repair and translesion synthesis.
authors.affiliation: Department of Respiratory Medicine, Southwest Hospital, Third Military Medical University, Chongqing 400038, China.
authors.forename: Chunlan
authors.initials: C
authors.lastname: Tang
authors.forename: Heping
authors.initials: H
authors.lastname: Yang
authors.forename: Xiangdong
authors.initials: X
authors.lastname: Zhou
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002945:Cisplatin / Q000627:therapeutic use*; D004249:DNA Damage; D004260:DNA Repair / Q000187:drug effects*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin